BRISTOL MYERS SQUIBB

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

Pharmacokinetic and Metabolism of [14^C] BMS-986177 in Healthy Male Participants

Phase 1

Completed

Conditions: Thrombosis

Interventions: Drug: BMS-986177

First Posted Date: 2019-05-07

Last Posted Date: 2019-10-04

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 9

Registration Number: NCT03939702

Locations: 🇺🇸
Covance Clinical Research Unit, Inc., Madison, Wisconsin, United States

A Study to Evaluate the Effect of Omeprazole on the Pharmacokinetics of BMS-986205 in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BMS-986205
Drug: omeprazole

First Posted Date: 2019-05-03

Last Posted Date: 2019-09-23

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 16

Registration Number: NCT03936374

Locations: 🇺🇸
PPD Phase I Clinic, Austin, Texas, United States

Safety and Efficacy of Deucravacitinib in Participants With Moderate to Severe Ulcerative Colitis

Phase 2

Completed

Conditions: Ulcerative Colitis

Interventions: Drug: BMS-986165
Other: Placebo

First Posted Date: 2019-05-01

Last Posted Date: 2024-03-06

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 131

Registration Number: NCT03934216

Locations: 🇺🇸
Penn State Health Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States
🇧🇪
Local Institution - 0065, Brussels, Belgium
🇩🇪
Charite Universitatsmedizin Berlin - Campus Virchow-Klinikum, Berlin, Germany

and more 98 locations

Study to Characterize the Effects of Cytochrome p450 1A2 Inhibition on Systemic Exposure to BMS-986165

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BMS-986165
Drug: Fluvoxamine

First Posted Date: 2019-04-29

Last Posted Date: 2021-11-17

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 16

Registration Number: NCT03930602

Locations: 🇺🇸
ICON Plc (PRA Health Sciences), Salt Lake City, Utah, United States

An Investigational Study to Evaluate Experimental Medication BMS-986165 in Japanese Participants With Moderate-to-Severe Psoriasis

Phase 3

Completed

Conditions: Psoriasis

Interventions: Drug: BMS-986165

First Posted Date: 2019-04-23

Last Posted Date: 2022-11-02

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 74

Registration Number: NCT03924427

Locations: 🇯🇵
Yokohama City University Hospital, Yokohama, Kanagawa, Japan
🇯🇵
Hamamatsu University Hospital, Hamamatsu, Shizuoka, Japan
🇯🇵
Kyoto University Hospital, Kyoto-City, Kyoto, Japan

and more 23 locations

Long-Term Safety and Efficacy Study of Deucravacitinib in Participants With Systemic Lupus Erythematosus

Phase 2

Active, not recruiting

Conditions: Systemic Lupus Erythematosus

Interventions: Drug: BMS-986165

First Posted Date: 2019-04-18

Last Posted Date: 2024-05-30

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 261

Registration Number: NCT03920267

Locations: 🇨🇦
Local Institution - 0136, Toronto, Ontario, Canada
🇵🇱
Local Institution - 0018, Krakow, Poland
🇧🇷
Local Institution - 0106, Juiz de Fora, Minas Gerais, Brazil

and more 94 locations

Pan Tumor Rollover Study

Phase 2

Recruiting

Conditions: Cancer

Interventions: Drug: Nivolumab
Drug: Leucovorin
Drug: Nivolumab + Relatlimab
Drug: Regorafinib
Drug: Capecitabine
Drug: Pemetrexed
Drug: Enzalutamide
Drug: Sunitinib
Drug: Pembrolizumab
Drug: Relatlimab
Drug: Temozolomide
Drug: Rucaparib
Drug: Ipilimumab
Drug: Daratumumab
Drug: Fluorouracil
Drug: Cabozantinib
Drug: Trametinib
Drug: Bevacizumab
Drug: Oxaliplatin

First Posted Date: 2019-04-02

Last Posted Date: 2024-11-19

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 1500

Registration Number: NCT03899155

Locations: 🇧🇷
Local Institution - 0260, Belo Horizonte, Minas Gerais, Brazil
🇨🇳
Harbin Medical University - Cancer Hospital, Harbin, Heilongjiang, China
🇨🇳
Local Institution - 0172, Changsha, Hunan, China

and more 304 locations

A Study to Assess the Safety of Experimental Medication BMS986165 in Participants With Normal Kidney Function and Participants With Mild to End-Stage Kidney Disease.

Phase 1

Completed

Conditions: Healthy Volunteer
Renal Impairment

Interventions: Drug: BMS-986165

First Posted Date: 2019-03-26

Last Posted Date: 2021-03-12

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 44

Registration Number: NCT03890770

Locations: 🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States
🇭🇺
Szent Imre Egyetemi Oktatokorhaz, Budapest, Hungary
🇨🇿
Pharmaceutical Research Associates CZ, s.r.o, Praha 7, Czechia

and more 3 locations

An Investigational Study of BMS-986165 in Participants With Normal Liver Function and Participants With Mild to Severe Liver Damage

Phase 1

Completed

Conditions: Healthy Volunteers
Liver Dysfunction

Interventions: Drug: BMS-986165

First Posted Date: 2019-03-26

Last Posted Date: 2020-08-26

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 32

Registration Number: NCT03890809

Locations: 🇭🇺
Kenezy Gyula Korhaz es Rendelointezet, Debrecen, Hungary
🇭🇺
Clinical Research Unit Hungary, Miskolc, Hungary
🇨🇿
Pharmaceutical Research Associates CZ, s.r.o, Praha 7, Czechia

and more 1 locations

A Pharmacokinetics, Safety and Tolerability Study of Multiple Formulations of BMS-986231 in Healthy Participants

Phase 1

Completed

Conditions: Heart Failure

Interventions: Drug: BMS-986231 Formulation C
Drug: BMS-986231 Formulation D
Drug: BMS-986231 Formulation B
Drug: BMS-986231 Formulation A

First Posted Date: 2019-03-26

Last Posted Date: 2019-10-01

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 60

Registration Number: NCT03891108

Locations: 🇺🇸
PRA Health Sciences, Salt Lake City, Utah, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy